Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study

Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li, Rongjun Shen, Heidi K. Leister-Tebbe, Steven G. Terra, Michael Gaffney, Leo Russo
doi: https://doi.org/10.1101/2022.09.13.22279908

Article Information

doi 
https://doi.org/10.1101/2022.09.13.22279908
History 
  • September 14, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Xiaofeng Zhou, PhD1,*,
  2. Scott P. Kelly, PhD1,
  3. Caihua Liang, MD, PhD1,
  4. Ling Li, MS1,
  5. Rongjun Shen, MS1,
  6. Heidi K. Leister-Tebbe, BSN2,
  7. Steven G. Terra, PharmD3,
  8. Michael Gaffney, PhD4 and
  9. Leo Russo, PhD5
  1. 1Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA
  2. 2Global Product Development, Pfizer Inc, Collegeville, PA, USA
  3. 3Global Product Development, Pfizer Inc, Andover, MA, USA
  4. 4Statistical Research, Pfizer Inc, New York, NY, USA
  5. 5Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc, Collegeville, PA, USA
  1. ↵* Corresponding author; email: xiaofeng.zhou{at}pfizer.com
Back to top
Posted September 14, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study
Xiaofeng Zhou, Scott P. Kelly, Caihua Liang, Ling Li, Rongjun Shen, Heidi K. Leister-Tebbe, Steven G. Terra, Michael Gaffney, Leo Russo
medRxiv 2022.09.13.22279908; doi: https://doi.org/10.1101/2022.09.13.22279908
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area